T. Rowe Price Associates’s Orchestra BioMed OBIO Stock Holding History

T. Rowe Price Associates’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$142K	Buy	+32,689	New	+$134K	﹤0.01%	3092
2026 Q1	–	Sell	-364,645	Closed	-$1.51M	–	3178
2025 Q4	$1.51M	Sell	364,645 -56,967	-14%	-$230K	﹤0.01%	1891
2025 Q3	$1.05M	Sell	421,612 -16,757	-4%	-$46.2K	﹤0.01%	2048
2025 Q2	$1.18M	Sell	438,369 -21,751	-5%	-$63.5K	﹤0.01%	1913
2025 Q1	$1.97M	Sell	460,120 -27,050	-6%	-$134K	﹤0.01%	1612
2024 Q4	$1.95M	Sell	487,170 -25,493	-5%	-$137K	﹤0.01%	1661
2024 Q3	$2.64M	Sell	512,663 -40,040	-7%	-$262K	﹤0.01%	1517
2024 Q2	$4.51M	Sell	552,703 -18,372	-3%	-$106K	﹤0.01%	1249
2024 Q1	$3.01M	Sell	571,075 -51,533	-8%	-$349K	﹤0.01%	1379
2023 Q4	$5.68M	Sell	622,608 -2,012	-0.3%	-$13.7K	﹤0.01%	1180
2023 Q3	$5.45M	Sell	624,620 -22,837	-4%	-$154K	﹤0.01%	1161
2023 Q2	$4.53M	Sell	647,457 -33,090	-5%	-$502K	﹤0.01%	1213
2023 Q1	$13.3M	Sell	680,547 -5,254	-0.8%	-$60.8K	﹤0.01%	1007
2022 Q4	$6.85M	Sell	685,801 -38,764	-5%	-$386K	﹤0.01%	1120
2022 Q3	$7.18M	Sell	724,565 -2,637	-0.4%	-$26.1K	﹤0.01%	1128
2022 Q2	$7.24M	Sell	727,202 -66,876	-8%	-$665K	﹤0.01%	1371
2022 Q1	$7.87M	Sell	794,078 -4,605	-0.6%	-$45.5K	﹤0.01%	1402
2021 Q4	$7.99M	Sell	798,683 -9,082	-1%	-$89.5K	﹤0.01%	1439
2021 Q3	$7.99M	Sell	807,765 -2,373	-0.3%	-$23.4K	﹤0.01%	1451
2021 Q2	$8.26M	Sell	810,138 -39,862	-5%	-$412K	﹤0.01%	1439
2021 Q1	$9.55M	Hold	850,000	–	–	﹤0.01%	1403
2020 Q4	$10.9M	Hold	850,000	–	–	﹤0.01%	1339
2020 Q3	$9.35M	Buy	+850,000	New	+$9.54M	﹤0.01%	1315

Other funds holding OBIO

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

T. Rowe Price Associates's OBIO Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Orchestra BioMed (OBIO) in Q2 2026: 32,689 shares worth $142K. The stake represents ﹤0.01% of the portfolio and ranks #3092 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in OBIO as recently as Q4 2025.

T. Rowe Price Associates first reported a position in OBIO in Q3 2020 and has held it in 23 quarters since. The position peaked at $13.3M in Q1 2023. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

T. Rowe Price Associates held 32,689 shares of Orchestra BioMed worth $142K as of Q2 2026.
Orchestra BioMed was a new T. Rowe Price Associates position in Q2 2026.
Orchestra BioMed made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3092 holding.
T. Rowe Price Associates first reported a position in Orchestra BioMed in Q3 2020 and has held it in 23 quarters since.
T. Rowe Price Associates's Orchestra BioMed position peaked at $13.3M in Q1 2023.
77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.